Natco Pharma stock heads toward a INR 12.7935 billion rights issue

Published on 10/07/2026 at 02:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natco Pharma stock is preparing for a INR 12.7935 billion rights issue opening October 12, 2026. Q1 FY27 revenue fell 42.9 percent year over year.

Natco, INE987B01026, Illustration mit AI erstellt.

Natco Pharma (ISIN INE987B01026) was last at INR 823.65 on the NSE on October 6, 2026, up 0.26 percent from the previous close. The company is preparing a INR 12.7935 billion rights issue at INR 750 per share, with subscriptions scheduled to open October 12, 2026.

Rights issue sets the next checkpoint

According to The Hindu BusinessLine on September 25, 2026, Natco approved up to 17,058,082 new shares at INR 750 each, offering two rights shares for every 21 shares held on the October 1 record date. The issue is scheduled to close on October 22, 2026.

Full subscription would lift the share count from 179,109,870 to 196,167,952, according to The Hindu BusinessLine. That implies a larger equity base, making the subscription terms and the use of proceeds central to the stock story in October.

Q1 revenue fell 42.9 percent

Natco's latest reported quarter was Q1 FY27. Quartr reported consolidated revenue of INR 7,944 million, down from INR 13,906 million in Q1 FY26, a 42.9 percent year-over-year decline.

Profit after tax fell to INR 2,065 million from INR 4,803 million, a 57 percent decline, while EBITDA reached INR 2,457 million at a 30.9 percent margin. The contrast matters because the rights issue arrives while the business is rebuilding earnings after lower lenalidomide sales.

Stock remains below yearly high

Natco Pharma's October 6 session range was INR 815.35 to INR 825.80, with volume of 225,103 shares. The 52-week range was INR 792.05 to INR 1,226.80, placing the last price 32.8 percent below the high and 4.0 percent above the low.

Market capitalization stood at INR 147.5 billion as of October 6, 2026. For investors, the key comparison is clear: the INR 750 rights price sits below the last market price, while the Q1 revenue and profit declines show why capital allocation and the next earnings cycle matter.

Natco Pharma stock heads into the rights window

Natco Pharma was last at INR 823.65 on the NSE on October 6, 2026 at 3:29 p.m. IST. The rights issue opens October 12 and closes October 22, 2026, giving the stock a defined corporate-action timetable.